BPH confirms intention to enter medical cannabis sector
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Diversified investment group BPH Energy Ltd (ASX:BPH) has advised of its intention to pursue a complementary strategy of making investments in the medical cannabis sector.
This announcement comes on the back of an ASX query which sought an explanation for the change in the price of the company’s shares from a closing price of $0.001 on Thursday, October 18 to an intra-day high at the time of writing of $0.003 on Friday.
The regulator also noted the significant increase in trading volumes with an all-time record 56 million shares traded.
While the company was in the process of resolving the terms of a rights issue and, separately, an internal proposal to consider investing into the medical cannabis sector, neither of which had been finalised or approved by the Board, management didn’t feel that confidentiality had been lost regarding these proposed initiatives.
BPH to recommence trading on Thursday
However, with the terms of the rights issue now settled and confirmation of its intention to invest in the medical cannabis sector in the public domain, BPH has recommenced trading on Thursday.
Management is buoyed by the significant growth occurring in the medical cannabis sector, as well as positive regulatory developments within the industry, including the move to legalise cannabis in Canada and the announcement by the British government to legalise medical cannabis from November 2018.
Of course, this follows the decision by the Australian Federal Government to legalise the export of medical cannabis from Australia in January this year.
Consequently, management’s intention is to inject most of the funds raised from the $1.18 million rights issue into a cannabis industry related investment.
Opportunity to increase stake in Cortical Dynamics
Looking across the company’s other investments, Cortical Dynamics Ltd is in the process of undertaking a pre-IPO capital raising of up to $2 million at a price of 10 cents per share.
BPH has a 4.47% interest in Cortical Dynamics, as well as a right to convert debt and increase its shareholding in the group which could take its stake to approximately 15.7%.
Cortical Dynamics is working with the Swinburne University of Technology to develop and commercialise a unique depth of anaesthesia monitoring system for use during major surgery.
The core technology is based on real time analysis of the patient’s electroencephalograph (“EEG”) using a proprietary algorithm based on a mathematically and physiologically detailed understanding of the brain’s rhythmic electrical activity.
TGA and CE Mark certification
Cortical recently received notification from the Therapeutic Goods Administration (TGA) that a decision was made to issue a conformity assessment certificate to the company.
In addition to this, Cortical also received notification that it would be issued MRA EC certificates (CE Mark) under the Mutual Recognition Agreement (MRA) with the European Union, allowing the CE Mark to be applied to the BAR monitor.
Having achieved TGA certification and the CE Mark, Cortical is now able to market the BAR monitor within Australia and Europe.
With positive developments on a number of fronts investors will be keen to see if the recent share price momentum can be sustained.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
